CD8A and acute myeloid leukemia: These results show that the WT1-loaded mo-DCs used as autologous vaccines in AML patients also express the TAA RHAMM at sufficient levels to potently activate RHAMM-specific cytotoxic CD8+ T cells in an HLA-dependent manner.